Averitas Pharma Revenue and Competitors
Estimated Revenue & Valuation
- Averitas Pharma's estimated annual revenue is currently $35.8M per year.
- Averitas Pharma's estimated revenue per employee is $201,000
Employee Data
- Averitas Pharma has 178 Employees.
- Averitas Pharma grew their employee count by 8% last year.
Averitas Pharma's People
Name | Title | Email/Phone |
---|---|---|
1 | Head HR, Averitas Pharma, US | Reveal Email/Phone |
2 | VP, Marketing Strategy & Operations | Reveal Email/Phone |
3 | SVP, US Commercial | Reveal Email/Phone |
4 | Midatlantic Regional Business Director | Reveal Email/Phone |
5 | Regional Business Director | Reveal Email/Phone |
6 | Director Field Access | Reveal Email/Phone |
7 | Regional Business Director | Reveal Email/Phone |
8 | Regional Business Director - Gulf Coast | Reveal Email/Phone |
9 | Area Business Director | Reveal Email/Phone |
10 | Associate Director, QUTENZA Marketing | Reveal Email/Phone |
Averitas Pharma Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5M | 25 | -11% | N/A | N/A |
#2 | $35.8M | 178 | 8% | N/A | N/A |
#3 | $5.4M | 27 | -25% | N/A | N/A |
#4 | $4180M | 14516 | 1% | $550M | N/A |
#5 | $12.5M | 62 | 15% | N/A | N/A |
#6 | $6.7M | 119 | -37% | $199.6M | N/A |
#7 | $9.4M | 47 | 7% | N/A | N/A |
#8 | $10.3M | 51 | 6% | N/A | N/A |
#9 | $106.3M | 529 | 16% | N/A | N/A |
#10 | $15.5M | 77 | 20% | N/A | N/A |
What Is Averitas Pharma?
At Averitas Pharma, we strive to enable people with pain to live and feel more like their true selves. With patients at the forefront of every decision we make, we want more than to envision people not limited by their pain; we work every day with passion and determination to make it a reality. We are currently helping patients by offering the only FDA-approved, non-opioid, topical system for the treatment of neuropathic pain associated with postherpetic neuralgia (post-shingles nerve pain) and for neuropathic pain associated with diabetic peripheral neuropathy of the feet (diabetic nerve pain of the feet). We are proudly building on the 75-year legacy of Grünenthal, a global privately held healthcare company that has been working tirelessly toward a world free of pain by approaching pain as a disease in urgent need of a solution, rather than a mere symptom. We do it because we care. Most of us have either dealt with chronic pain or know someone who has, because it is a burden that far too many people around the world must bear. Our empathy for patients, and our shared sense of mission and purpose, are what inspires us to keep going. And our people are the key to our success. For more information, visit www.averitaspharma.com Community Guidelines: 1. We reserve the right to remove profanity, threatening or harassing content, promotional content and any personal information. 2. Due to FDA fair balance rules, we ask that you not mention any medicines or FDA-approved therapies by name or include links to third-party sites. 3. This site is not a forum for reporting side effects experienced while using an Averitas product. Physicians, other healthcare providers, and patients are encouraged to voluntarily report adverse events involving drugs or medical devices. To make a report you can visit www.fda.gov/medwatch or call 1-800-FDA-1088 For questions about our products call 1-877-900-6479. For more information, ask your healthcare provider or or pharmacist.
keywords:N/AN/A
Total Funding
178
Number of Employees
$35.8M
Revenue (est)
8%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $49.2M | 179 | -30% | N/A |
#2 | $44.3M | 183 | 6% | N/A |
#3 | $37.4M | 186 | 6% | N/A |
#4 | $68.6M | 193 | 8% | N/A |
#5 | $57.6M | 194 | 11% | N/A |